{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:07:04Z","timestamp":1787929624893,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AJOG Global Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xagr.2025.100584","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T06:51:34Z","timestamp":1762584694000},"page":"100584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain"],"prefix":"10.1016","volume":"6","author":[{"given":"Jin Hee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Snabes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xagr.2025.100584_bib0001","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/0167482X.2015.1074173","article-title":"Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference","volume":"36","author":"Facchin","year":"2015","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(21)00389-5","article-title":"Endometriosis is a chronic systemic disease: clinical challenges and novel innovations","volume":"397","author":"Taylor","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xagr.2025.100584_bib0003","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMcp1000274","article-title":"Clinical practice: endometriosis","volume":"362","author":"Giudice","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xagr.2025.100584_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpobgyn.2018.06.001","article-title":"Risk for and consequences of endometriosis: a critical epidemiologic review","volume":"51","author":"Shafrir","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10815-010-9436-1","article-title":"Endometriosis and infertility","volume":"27","author":"Bulletti","year":"2010","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.xagr.2025.100584_bib0006","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41574-019-0245-z","article-title":"Rethinking mechanisms, diagnosis and management of endometriosis","volume":"15","author":"Chapron","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.xagr.2025.100584_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225615","article-title":"The pathogenesis of endometriosis: molecular and cell biology insights","volume":"20","author":"Lagan\u00e0","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xagr.2025.100584_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xagr.2025.100584_bib0009","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1089\/jwh.2020.8989","article-title":"Bone mineral density changes associated with pregnancy, lactation, and medical treatments in premenopausal women and effects later in life","volume":"30","author":"Watts","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.xagr.2025.100584_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejogrb.2009.05.007","article-title":"Repetitive surgery for recurrent symptomatic endometriosis: what to do?","volume":"146","author":"Vercellini","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.xagr.2025.100584_bib0011","series-title":"ORILISSA\u00ae (elagolix) tablets [Prescribing Information]","year":"2023"},{"key":"10.1016\/j.xagr.2025.100584_bib0012","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0013","doi-asserted-by":"crossref","first-page":"630.e1","DOI":"10.1016\/j.ajog.2024.06.040","article-title":"Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial","volume":"231","author":"Miller","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0014","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0029-7844(97)00620-0","article-title":"Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study","volume":"91","author":"Hornstein","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0016","first-page":"709","article-title":"Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up","volume":"99","author":"Surrey","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2025.100584_bib0017","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xagr.2025.100584_bib0018","article-title":"Gonadotropin-releasing hormone (GnRH)\/GnRH receptors and their role in the treatment of endometriosis","volume":"15","author":"Resta","year":"2023","journal-title":"Cureus"}],"container-title":["AJOG Global Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666577825001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666577825001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:59:48Z","timestamp":1773917988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666577825001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666577825001455"],"URL":"https:\/\/doi.org\/10.1016\/j.xagr.2025.100584","relation":{},"ISSN":["2666-5778"],"issn-type":[{"value":"2666-5778","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain","name":"articletitle","label":"Article Title"},{"value":"AJOG Global Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xagr.2025.100584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100584"}}